Personalized Medicine in Acute Infectious Diseases
| Reference number | |
| Coordinator | Karolinska Institutet - Centrum för infektionsmedicin |
| Funding from Vinnova | SEK 10 562 662 |
| Project duration | April 2019 - December 2024 |
| Status | Completed |
Important results from the project
The project aimed to drive the development of personalized medicine in severe infectious diseases, such as sepsis. This is motivated by the multifactorial nature of the disease, where each patient´s immune response is unique and directly linked to the course of the disease. The project has resulted in a strong Nordic interdisciplinary network in sepsis, and the results have identified promising candidates for improved diagnostics, prognostication, and more efficient personalized treatment.
Expected long term effects
The project is expected to result in increased innovation through the development of new diagnostic tools, as well as direct patient benefit through improved diagnostics, prognosis calculation and more efficient treatment. This has the potential to reduce the risk of complications and increase patient survival. Individualized treatment leads to a more efficient use of healthcare resources, which is more cost-effective.
Approach and implementation
The project was carried out by an interdisciplinary team of clinicians and researchers. The project included the collection and analysis of clinical data and biological samples from patients. As sepsis patients are cared for in the emergency room, intensive care and infection departments, patient recruitment had to be interrupted during the COVID-19 pandemic. However, the pandemic provided an opportunity to study COVID-19 patients in comparison with sepsis patients, which provided new knowledge.